From: Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of AI424138 (CASTLE)
Efficacy at Week 48 | ATV/r N = 61 | LPV/r N = 51 |
---|---|---|
HIV RNA<50 c/mL, CVR (Non-Completer = Failure), n/N (%) | 42/61 (69) | 37/51 (73) |
Mean CD4 Cell Count Change from Baseline (SE), cells/mm3 | 196 (26.1) | 228 (21.7) |